Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

120 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Kantarjian H, et al. N Engl J Med. 2017 Mar 2;376(9):836-847. doi: 10.1056/NEJMoa1609783. N Engl J Med. 2017. PMID: 28249141 Free PMC article. Clinical Trial.
Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity.
Ramji K, Grzywa TM, Sosnowska A, Paterek A, Okninska M, Pilch Z, Barankiewicz J, Garbicz F, Borg K, Bany-Laszewicz U, Zerrouqi A, Pyrzynska B, Rodziewicz-Lurzynska A, Papiernik D, Sklepkiewicz P, Kedzierska H, Staruch A, Sadowski R, Ciepiela O, Lech-Maranda E, Juszczynski P, Mackiewicz U, Maczewski M, Nowis D, Golab J. Ramji K, et al. Sci Rep. 2022 Nov 16;12(1):19660. doi: 10.1038/s41598-022-24137-1. Sci Rep. 2022. PMID: 36385153 Free PMC article.
Clinical efficacy and tolerability of venetoclax plus rituximab in patients with relapsed or refractory chronic lymphocytic leukemia-a real-world analysis of the Polish Adult Leukemia Study Group.
Soboń A, Drozd-Sokołowska J, Paszkiewicz-Kozik E, Popławska L, Morawska M, Tryc-Szponder J, Bołkun Ł, Rybka J, Pruszczyk K, Juda A, Majeranowski A, Iskierka-Jażdżewska E, Steckiewicz P, Wdowiak K, Budziszewska B, Jamroziak K, Hus I, Lech-Marańda E, Puła B. Soboń A, et al. Among authors: lech maranda e. Ann Hematol. 2023 Aug;102(8):2119-2126. doi: 10.1007/s00277-023-05304-4. Epub 2023 Jul 1. Ann Hematol. 2023. PMID: 37392368 Free PMC article.
Molnupiravir is effective in patients with haematological malignancies.
Bołkun Ł, Pula B, Kołkowska-Leśniak A, Morawska M, Cichocka E, Charlinski G, Garus B, Giebel S, Piszcz J, Drozd-Sokolowska J, Kwiatkowski J, Biernat M, Hus I, Lech-Maranda E, Długosz-Danecka M, Giannopoulos K, Wróbel T. Bołkun Ł, et al. Int J Cancer. 2023 Sep 15;153(6):1251-1256. doi: 10.1002/ijc.34442. Epub 2023 Feb 7. Int J Cancer. 2023. PMID: 36691818
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Anti-CD20-atezolizumab-polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma.
Topp MS, Eradat H, Florschütz A, Hochhaus A, Wrobel T, Walewski J, Knopinska-Posluszny W, Kanate AS, Lech-Maranda E, Brunnberg U, Chitra S, Nielsen TG, Sellam G, Shivhare M, Lossos IS. Topp MS, et al. J Cancer Res Clin Oncol. 2023 Feb;149(2):811-817. doi: 10.1007/s00432-021-03847-5. Epub 2022 Feb 18. J Cancer Res Clin Oncol. 2023. PMID: 35182224 Free PMC article.
Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.
Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Michallet AS, Warzocha K, Biliński P, Boyle P, Coiffier B, Salles G. Lech-Maranda E, et al. Arch Immunol Ther Exp (Warsz). 2013 Apr;61(2):165-74. doi: 10.1007/s00005-012-0215-9. Epub 2013 Jan 3. Arch Immunol Ther Exp (Warsz). 2013. PMID: 23283519 Free article.
120 results